The primary objective of this study is to test if the experimental drugs named Selonsertib (also known as "SEL"), GS-0976, GS-9674, and combinations of these drugs are safe, well-tolerated, and whether they can reduce fibrosis and the associated complications in subjects with fibrosis due to NASH.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study ATLAS
View study details on ClinicalTrials.gov
Subjects 18-80 years of age with bridging ( F3) fibrosis or compensated cirrhosis (F4) due to NASH with exclusion of other causes of liver disease based on medical history and/or centralized review of liver histology and prior history of decompensated liver disease including ascites, HE, or variceal bleeding.
June 01, 2018